Evotec Selected Advance Ebola Antibody Manufacturing
Evotec SE announced its Seattle-based subsidiary and CDMO, Just - Evotec Biologics, Inc., has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimization for a monoclonal antibody cocktail targeting filovirus diseases, including Ebola virus (EBOV) and Sudan virus (SUDV).
The multi-year program award, valued at up to $10 m if all options are activated, will support BARDA’s efforts to strengthen national preparedness by supporting the development of cost‑effective medical countermeasures that can augment the U.S. government’s response capabilities with therapeutics targeting filovirus diseases. The agreement has a base period and two option periods. While two FDA approved therapeutics are currently available for Ebola Virus Disease, no approved treatments exist for infections caused by SUDV.
Linda Zuckerman, PhD, EVP Global Head of Biotherapeutics at Just – Evotec Biologics commented: “In outbreak scenarios, speed, scalability and manufacturing robustness are critical. Our technology-driven approach is designed to deliver resilient, industry-leading high-yield production processes that can support rapid deployment in public health emergencies.”
Under the agreement, Just - Evotec Biologics will utilize its validated technology platforms to perform molecular optimization, cell line development, and manufacturing process development for two antibodies. These antibodies, originally identified in survivors of the 2014 Ebola outbreak, represent aspects of an immune response that may have protected infected individuals. Just - Evotec Biologics will apply its platform technologies to convert these discoveries into high-yield, scalable and cost-efficient manufacturing processes capable of supporting future therapeutic development and emergency deployment.
This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
